Pharma Stands Up To Trump Pressure With COVID-19 Vaccines Science Pledge

New US Poll Shows Public Distrust

CEOs from the most advanced vaccines developers pledge to maintain standards – for the sake of safety, efficacy and public trust in vaccines.

single Sars-cov-2 coronavirus vaccine
The timing of a potential approval has become a political issue ahead of the election - and is undermining US public faith in COVID-19 vaccines.

Chief executives of nine US and European biopharma companies leading COVID-19 vaccines development have come together to pledge that safety and efficacy will not be compromised in order to gain rapid approval for their products.

The companies include Pfizer Inc./BioNTech SE, Moderna, Inc. and AstraZeneca PLC, which say they could still...

More from Business

More from Scrip

Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach

 
• By 

A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.

Pharma Gets A Compatriot At CDER With Tidmarsh Appointment To Top Spot

 

Drug manufacturers may find comfort in the appointment of former biotech CEO and entrepreneur George Tidmarsh to lead the FDA’s Center for Drug Evaluation and Research.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.